ClinicalTrials.gg
Not yet recruitingNCT06458686Updated Jun 13, 2024

Effect of Vitamin D Supplementation on Mental Health: An Exploratory Study on A University Students Suffering From Vitamin D Deficiency

A Phase 1/2 interventional study of Vit D and Placebo in Psychiatric Disorder, sponsored by German University in Cairo. Not yet recruiting. Open to participants aged 18 Years to 22 Years. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by German University in Cairo · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 22 Years
Sex
All
01

Study summary

University students are susceptible to psychological burdens such as depressive symptoms, anxiety, and stress which might have been linked to vitamin D deficiency. Low serum vitamin D level is well recognized around the world. Vitamin D has been reported to modulate several neurological pathways in the brain that control psychological function. As a result, the purpose of this study is to evaluate the effect of vitamin D supplementation on the presence of depressive symptoms, anxiety, and stress in university students. The study will include two phases. The first phase is a cross-sectional phase assessing the prevalence vitamin D deficiency in addition to psychological symptoms. The second phase is a randomized controlled clinical trial that aims to assess the effect of vitamin D supplementation on the prevalent psychological symptoms and its impact on the academic performance among university students. The study will look at the relationship between mental health and vitamin D deficiency, as well as how it will affect academic performance of university students.

02

Conditions studied

  • Psychiatric Disorder

Browse trials for

03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 70 is below the median of 100 across 1,305 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

German University in Cairo is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For phase 1: sample will be selected using convenient sampling method where all students with an age range 18-22 years old fulfilling the eligibility criteria will be educated about the study protocol and will be asked to participate in the study.

For phase 2: students who diagnosed with deficient vitamin D level will be asked to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • to oral vitamin D supplements such as Diviton or Vidrop.

    • Students taking medications affecting vitamin D metabolism such as anti-seizure medications: phenytoin, phenobarbital and carbamazepine, isotretinoin, : dexamethasone, antibiotics: isoniazid and rifampin and antifungals: clotrimazole.
    • Students taking antidepressants, drug for bipolar disorder treatment like lithium and antipsychotic agents like olanzapine.
    • Students with insufficient vitamin D level (20-30 ng/mL).
    • Students with confirmed diagnosis with psychiatric illness.
    • Students with a history of liver disease or dysfunction.
    • Students with a history of kidney disease or dysfunction.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Placebo comparator
    Control group

    This group does not take any drug. It will take placebo.

    Other: Placebo

  • Active comparator
    Intervention group

    This group will take Vitamin D

    Drug: Vit D

Interventions

  • DrugVitamin DStudies of Vitamin DVitamin D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vitamin D is a fat soluble vitamin used for the treatment of many diseases.

  • OtherPlacebo

    Placebo is a non drug formulation

06

What researchers measure

Primary outcomes

  1. Evaluation of the correlation between vitamin D deficiency and presence and severity of anxiety, stress and depressive symptoms.

    Evaluation of the correlation between vitamin D deficiency and presence and severity of anxiety, stress and depressive symptoms.

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for Jun 2026, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2024
First posted
Jun 13, 2024
StartEst.
Jun 30, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06458686
Lead sponsor
German University in Cairo
Collaborators
Prof. Mohamed Hassan Solayman, Clinical pharmacy Department, German University in Cairo, Prof. May Ahmed Shawki, Clinical Pharmacy Department, Ain Shams University, Egypt
Responsible party
Nouran Hussien Kandeel (Nouran hussien kandeel, German University in Cairo) — Principal investigator
First posted
Jun 13, 2024
Start date
Jun 30, 2024 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jun 13, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin D

Start the discussion